Core Insights - Prenetics Global Limited has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million purchase of 187.42 BTC at an average price of $106,712 per Bitcoin [2][17] - The company aims to significantly increase its Bitcoin holdings and become one of the largest corporate Bitcoin holders in the healthcare sector, inspired by strategies from MicroStrategy and Metaplanet [1][3][8] - Prenetics has appointed Andy Cheung, former COO of OKEx, to its Board of Directors to provide strategic oversight for its Bitcoin treasury initiative [3][5] Financial Strategy - Prenetics has a strengthened balance sheet with over $117 million in total liquidity, including approximately $66 million in cash reserves and a debt-free balance sheet [15] - The Board has approved a majority allocation of its balance sheet to Bitcoin, demonstrating a strong commitment to digital asset adoption [9] - The company is actively discussing partnerships with leading financial institutions to develop a long-term Bitcoin acquisition plan [10] Operational Integration - Prenetics plans to accept cryptocurrency payments across its direct-to-consumer platforms, creating a seamless Bitcoin ecosystem from treasury to operations [11] - The company is implementing sophisticated alpha-generating strategies to maximize returns on its Bitcoin holdings, including yield generation and strategic lending [10] Business Growth - Prenetics has increased its full-year 2025 revenue guidance to $80-100 million, indicating confidence in its core business trajectory [12] - The company has achieved significant growth with over 55,000 customers and a 91% subscription rate across its health brands [14] Leadership and Expertise - The strategic appointment of industry leaders like Andy Cheung and Tracy Hoyos Lopez enhances Prenetics' credibility and operational guidance in the crypto space [5][13] - The company is leveraging the expertise of its advisory team to navigate the complexities of corporate Bitcoin adoption and to architect the future intersection of healthcare and digital assets [7][8]

Core Viewpoint - Prenetics Global Limited has announced the divestment of its majority stake in ACT Genomics to Delta Electronics for up to US$71.78 million, enhancing its financial position and focusing on high-growth consumer health brands [1][3][5] Financial Position - The divestment will provide Prenetics with approximately US$46 million in cash, increasing its pro-forma cash reserves to about US$86 million and pro-forma short-term assets to US$117 million, while maintaining a debt-free balance sheet [1][8][17] - Prenetics raised its FY2025 revenue outlook to US$80 – US$100 million from the previous US$73 – US$85 million, driven by the growth of its IM8 brand [5][6] Strategic Transformation - The divestment is part of Prenetics' strategic transformation to simplify its business model and enhance financial flexibility, allowing for accelerated growth in the consumer health market [3][11] - Prenetics now focuses on three consumer health brands: IM8, CircleDNA, and Europa, which are expected to synergistically enhance its market position [4][7][11] Market Performance - Prenetics' consumer health business has shown significant momentum, with Q1 2025 revenue of US$14.4 million, representing a 336.5% year-over-year increase, and a projected Q2 revenue of US$8.5 million [6][8] - The company has acquired over 55,000 customers and achieved a 91% subscription rate, indicating strong market demand [6][8] Innovation and Future Outlook - With a robust cash position, Prenetics is positioned to explore innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies [10][11] - The company maintains a 35% stake in Insighta, valued at US$70 million, which adds significant value for shareholders [9]

[Executive Summary & Highlights](index=1&type=section&id=1.%20Executive%20Summary%20%26%20Highlights) Prenetics reported strong Q1 2025 financial performance, exceeding expectations, driven by consumer business growth and strategic realignment, with a raised full-year revenue outlook [First Quarter 2025 Financial Highlights](index=1&type=section&id=1.1%20First%20Quarter%202025%20Financial%20Highlights) Prenetics reported an exceptionally strong first quarter of 2025, with revenue from continuing operations increasing significantly and a raised full-year revenue outlook, as the consumer business, particularly IM8, demonstrated robust growth | Metric | Q1 2025 (USD) | Q1 2024 (USD) | YoY Change | | :-------------------------------------- | :------------ | :------------ | :--------- | | Revenue (continuing operations) | $17.3 million | $6.4 million | +169.9% | | Consumer Business Revenue (excl. ACT Genomics) | $14.4 million | $3.3 million | +336.5% | | Gross Profit (continuing operations) | $7.3 million | $3.8 million | +94.1% | | Adjusted EBITDA Loss (continuing operations) | $(6.5) million | $(4.1) million | +59.4% (less negative) | - Raised full-year 2025 revenue outlook to **$80 - $100 million**, up from $73 - $85 million[5](index=5&type=chunk)[7](index=7&type=chunk) - IM8 contributed **$5.7 million** in Q1 2025, with Q2 revenue projected to reach approximately **$8.5 million**, representing a **50% quarter-over-quarter increase**[5](index=5&type=chunk)[7](index=7&type=chunk) - Cash and other short-term assets totaled **$78.0 million** as of March 31, 2025, and the Company remained debt-free[7](index=7&type=chunk) [Management Commentary](index=1&type=section&id=1.2%20Management%20Commentary) CEO Danny Yeung highlighted the strong Q1 performance, exceeding expectations, and the successful strategic realignment towards global consumer healthcare, emphasizing the company's robust financial foundation and pioneering crypto strategy for treasury management and capital allocation - The first quarter of 2025 marked an exceptionally strong start for Prenetics, with financial performance that significantly surpassed expectations and strategic advancements that position us for accelerated growth[4](index=4&type=chunk) - The strategic realignment towards the global consumer healthcare market is gaining tremendous traction[5](index=5&type=chunk) - The company is actively pioneering innovative approaches to treasury management and capital allocation, strategically embracing a crypto strategy and Bitcoin adoption to optimize shareholder value and revolutionize patient care[9](index=9&type=chunk) [Business Updates and Strategic Initiatives](index=2&type=section&id=2.%20Business%20Updates%20and%20Strategic%20Initiatives) This section details Prenetics' strong IM8 business momentum, strategic crypto advisory initiatives, increased full-year revenue outlook, and the ongoing strategic review of ACT Genomics [IM8 Business Momentum](index=2&type=section&id=2.1%20IM8%20Business%20Momentum) IM8 has achieved remarkable success in its first six months since launch, attracting over 55,000 customers and expanding its global footprint to 31 countries, demonstrating strong customer loyalty and market potential - IM8 has attracted over **55,000 customers** and delivered more than **4.9 million servings** of its flagship Daily Ultimate Essentials[10](index=10&type=chunk) - Achieved an industry-leading **91% subscription rate** and an impressive average order value of **US$109**[10](index=10&type=chunk) - Shipping now extended to **31 countries worldwide**, rapidly expanding its global footprint[10](index=10&type=chunk) [Strategic Crypto Advisory Initiatives](index=2&type=section&id=2.2%20Strategic%20Crypto%20Advisory%20Initiatives) Prenetics is actively developing an innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption, engaging with leading crypto industry veterans for expert guidance to optimize capital allocation and enhance shareholder value - Management is actively advancing an innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption[11](index=11&type=chunk) - Engaging in active discussions with leading crypto industry veterans and thought leaders to provide expert guidance[11](index=11&type=chunk) - This forward-thinking approach aims to optimize capital allocation and drive long-term shareholder value creation[11](index=11&type=chunk) [Outlook](index=2&type=section&id=2.3%20Outlook) The company has increased its full-year 2025 revenue guidance to $80-$100 million, driven by the exceptional growth of IM8, which is projected to reach $8.5 million in Q2 revenue - Increased full-year 2025 revenue guidance to **$80 to $100 million** from the previously projected $73 to $85 million[12](index=12&type=chunk) - IM8's second quarter revenue is expected to reach approximately **$8.5 million**, representing **50% quarter-over-quarter growth**[12](index=12&type=chunk) [ACT Genomics Strategic Review](index=2&type=section&id=2.4%20ACT%20Genomics%20Strategic%20Review) Prenetics is nearing the conclusion of its strategic review of ACT Genomics and expects to announce a decision regarding its ownership stake shortly - Significant progress has been made in the previously announced strategic review of ACT Genomics[8](index=8&type=chunk) - An announcement regarding the strategic decision on the ownership stake in ACT Genomics will be forthcoming[8](index=8&type=chunk) [Company Information](index=3&type=section&id=3.%20Company%20Information) This section provides an overview of Prenetics as a health sciences company and details about its premium core nutrition brand, IM8, co-founded by David Beckham [About Prenetics](index=3&type=section&id=3.1%20About%20Prenetics) Prenetics is a leading health sciences company focused on advancing consumer and clinical health, with key consumer initiatives including IM8 and Europa, aiming to enhance life through science - Prenetics (NASDAQ:PRE) is a leading health sciences company dedicated to advancing consumer and clinical health[13](index=13&type=chunk) - Consumer initiatives are led by IM8, a health and wellness brand, and Europa, one of the largest sports distribution companies in the USA[13](index=13&type=chunk) - The company's commitment is to 'enhancing life through science'[13](index=13&type=chunk) [About IM8](index=3&type=section&id=3.2%20About%20IM8) IM8 is a premium core nutrition brand, co-founded by David Beckham, offering science-backed health solutions, with its flagship product, Daily Ultimate Essentials, being an all-in-one powder supplement certified for sport and free from common allergens - IM8 is a premium core nutrition brand, born from a collaboration with David Beckham as a co-founding partner and an elite team of scientists[14](index=14&type=chunk) - Its flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements[14](index=14&type=chunk) - The product is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners[14](index=14&type=chunk) [Financial Information](index=3&type=section&id=4.%20Financial%20Information) This section outlines the basis of financial presentation, provides unaudited consolidated financial statements, reconciliations of non-IFRS measures, and notes to the financial statements [Basis of Presentation & Non-IFRS Financial Measures Explanation](index=3&type=section&id=4.1%20Basis%20of%20Presentation%20%26%20Non-IFRS%20Financial%20Measures%20Explanation) This section explains the basis of presentation for financial statements, including the use and definition of non-IFRS financial measures like Adjusted EBITDA, clarifying that these measures supplement IFRS, are not standardized, and have limitations, encouraging investors to review reconciliations - Non-IFRS measures provided include adjusted EBITDA loss from continuing operations, total revenue from continuing operations (normalized to exclude ACT Genomics), and total adjusted EBITDA from continuing operations (normalized to exclude ACT Genomics)[17](index=17&type=chunk) - These non-IFRS measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies[17](index=17&type=chunk) - Adjusted EBITDA is derived from loss for the period by excluding various non-cash and/or non-recurring items such as depreciation, amortization, interest income, income tax credit, share-based payment expenses, and fair value adjustments[6](index=6&type=chunk)[18](index=18&type=chunk) [Unaudited Consolidated Statements of Financial Position (Balance Sheet)](index=5&type=section&id=4.2%20Unaudited%20Consolidated%20Statements%20of%20Financial%20Position%20(Balance%20Sheet)) The unaudited consolidated balance sheet as of March 31, 2025, shows a slight decrease in total assets and total equity compared to December 31, 2024, while total liabilities increased marginally | Metric | March 31, 2025 (USD thousands) | December 31, 2024 (USD thousands) | Change | | :-------------------------------- | :----------------------------- | :------------------------------ | :----- | | Total Assets | 204,015 | 213,575 | (9,560) | | Current Assets | 78,024 | 86,148 | (8,124) | | Cash and Cash Equivalents | 47,966 | 52,251 | (4,285) | | Total Liabilities | 42,899 | 42,229 | 670 | | Total Equity | 161,116 | 171,346 | (10,230) | [Unaudited Consolidated Statements of Profit or Loss and Other Comprehensive Income (Income Statement)](index=6&type=section&id=4.3%20Unaudited%20Consolidated%20Statements%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income%20(Income%20Statement)) For Q1 2025, Prenetics reported a significant increase in revenue from continuing operations and gross profit compared to Q1 2024, but also an increased operating loss and net loss for the period | Metric | Q1 2025 (USD thousands) | Q1 2024 (USD thousands) | YoY Change | | :-------------------------------------- | :---------------------- | :---------------------- | :--------- | | Revenue (Continuing Operations) | 17,312 | 6,413 | +169.9% | | Direct Costs | (9,970) | (2,631) | +279.0% | | Gross Profit | 7,342 | 3,782 | +94.1% | | Operating Loss (Continuing Operations) | (10,632) | (9,160) | +16.1% (larger loss) | | Loss for the Period | (11,016) | (9,052) | +21.7% (larger loss) | | Basic Loss per Share | (0.80) | (0.70) | +14.3% (larger loss) | [Unaudited Non-IFRS Financial Measures Reconciliation](index=7&type=section&id=4.4%20Unaudited%20Non-IFRS%20Financial%20Measures%20Reconciliation) This section provides reconciliations for non-IFRS measures, showing an adjusted EBITDA loss from continuing operations of $(6.5) million for Q1 2025, and a normalized revenue (excluding ACT Genomics) of $14.4 million, with a corresponding normalized adjusted EBITDA loss of $(4.8) million | Metric | Q1 2025 (USD thousands) | Q4 2024 (USD thousands) | Q1 2024 (USD thousands) | | :---------------------------------------------------- | :---------------------- | :---------------------- | :---------------------- | | Adjusted EBITDA from continuing operations (Non-IFRS) | (6,545) | (9,414) | (4,106) | | Revenue normalized to exclude ACT Genomics (non-GAAP) | 14,411 | 6,563 | 3,301 | | Adjusted EBITDA normalized to exclude ACT Genomics (non-GAAP) | (4,763) | (7,448) | (2,129) | [Notes to Financial Statements](index=8&type=section&id=4.5%20Notes%20to%20Financial%20Statements) This section provides additional context for specific financial line items, including the nature of liabilities for puttable financial instruments related to ACT Genomics acquisition and the classification of COVID-19 testing and EMEA DNA testing operations as discontinued - Liabilities for puttable financial instrument arise from put options granted to remaining shareholders of ACT Genomics, valued at the present value of the exercise price[23](index=23&type=chunk) - The COVID-19 testing business (ceased Q2 2023) and other DNA testing operations in the EMEA regions (ceased Q4 2023) are reported as discontinued operations under IFRS 5[23](index=23&type=chunk) Employee Equity-Settled Share-Based Payment Expenses | Expense Category | Q1 2025 (USD) | Q4 2024 (USD) | Q1 2024 (USD) | | :------------------------------- | :---------- | :---------- | :---------- | | Direct costs | — | 39 | 1 | | Selling and distribution expenses | 1 | 153 | 1 | | Research and development expenses | 467 | 511 | 758 | | Administrative and other operating expenses | 390 | 2,049 | 1,156 | | **Total** | **858** | **2,752** | **1,916** | [Legal & Disclosure](index=3&type=section&id=5.%20Legal%20%26%20Disclosure) This section includes cautionary forward-looking statements and provides contact information for investor relations inquiries [Forward-Looking Statements](index=3&type=section&id=5.1%20Forward-Looking%20Statements) This section contains standard cautionary language regarding forward-looking statements, noting they are based on estimates and forecasts, involve inherent risks and uncertainties, and actual results may differ materially, with the company not undertaking to update this information - Statements are forward-looking, made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995, covering goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, and growth opportunities[15](index=15&type=chunk) - Forward-looking statements are based upon estimates and forecasts, reflecting views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties[15](index=15&type=chunk) - A number of factors could cause actual results to differ materially, including the Company's ability to develop and grow its business, execute new strategies, results of studies/trials, and M&A opportunities[15](index=15&type=chunk) [Investor Relations Contact](index=3&type=section&id=5.2%20Investor%20Relations%20Contact) Provides contact information for investor relations inquiries - Investor Relations contact emails: investors@prenetics.com, PRE@mzgroup.us, angela.hm.cheung@prenetics.com[15](index=15&type=chunk) - Contact person: Angela Cheung, Investor Relations / Corporate Finance, Prenetics Global Limited[15](index=15&type=chunk)

Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]

Core Viewpoint - Broad Arrow Auctions, a subsidiary of Hagerty, is set to host its inaugural Concorso d'Eleganza Villa d'Este Auction on May 24-25, 2025, featuring over 70 collectible classic cars, including significant historical models like the Ferrari 166 Spyder Corsa and the 1938 Talbot-Lago T150 C Spéciale Teardrop Coupé [1][2][3]. Company Overview - Broad Arrow Auctions is a leading global collector car auction house, founded in 2021, and has quickly become the fastest-growing auction house in its segment [28]. - The company is expanding its global footprint, with its first European auction taking place in May 2025 as the official auction house for the Concorso d'Eleganza Villa d'Este in Italy [28]. Auction Highlights - The auction will feature the first-ever public sale of the Ferrari 166 Spyder Corsa by Ansaloni, estimated between €5.5 million and €7.5 million, which is recognized as Enzo Ferrari's first customer competition car [10][11][13]. - Another highlight is the 1938 Talbot-Lago T150 C Spéciale Teardrop Coupé, estimated between €4.5 million and €6.5 million, known for its unique design and historical significance [4][9]. - Additional notable cars include the 1949 Talbot-Lago T26 Grand Sport Coupe, estimated at €1.2 million to €1.5 million, and the 1936 Maserati 6CM Factory Works, estimated at €850,000 to €950,000 [9][23]. Event Details - The auction will take place at Villa Erba, located on the shores of Lake Como, and is expected to attract renowned collectors seeking to enhance their collections with some of the most desirable classic automobiles [25][26].

Financial Performance - For the fiscal year ended December 31, 2024, the company generated total revenue of approximately $30.7 million, with $97.2 thousand from discontinued COVID-19 testing services[59] - The company incurred net losses of $190.5 million, $64.8 million, and $49.8 million for the years ended December 31, 2022, 2023, and 2024, respectively[71] - In Q4 2024, revenue from continuing operations grew 93.2% to $10.5 million, with gross profit of $3.9 million, up 46.1% from Q4 2023[202] - For the full year 2024, revenue from continuing operations increased 40.8% year-over-year to $30.6 million, with gross profit of $15.4 million, up 74.4% from 2023[202] - The gross margin improved to 50.3% from 40.6%[202] - In 2025, projected revenue is between $73 million to $85 million, representing a 350-450% year-over-year increase[203] Market and Competition - The commercial success of key products like CircleDNA and IM8 is contingent upon regulatory approvals, market acceptance, competitive pricing, and effective marketing strategies[60] - The consumer genetic testing market is highly competitive, with many established competitors posing a continuous threat to the success of the CircleDNA product line[63] - The company faces competition from other organizations in the genetic testing market, which may impact its market share and sales revenue[65] - The company’s ability to maintain and enhance its brand recognition is critical for attracting and retaining customers[86] Regulatory and Compliance Risks - The company has not been identified as a Commission-Identified Issuer under the Holding Foreign Companies Accountable Act for fiscal year 2024, mitigating some regulatory risks[41] - The PCAOB has successfully conducted inspections of Hong Kong-based audit firms, allowing the company to comply with U.S. regulatory requirements[41] - The company is subject to evolving regulatory risks in Hong Kong, which could impact its operations and capital structure[115] - The company’s products are classified as medical devices and are subject to rigorous regulatory oversight, which could result in significant costs and delays[136] - The company may be required to modify operations in response to changing privacy laws, which could adversely affect its reputation and financial condition[135] Operational Challenges - The company faces significant risks due to its historical reliance on COVID-19 testing revenue, which has now been discontinued, increasing the challenge of generating revenue from new products[59] - The company faces significant challenges in expanding its sales and marketing infrastructure, which is currently limited and requires substantial resources for hiring and training[91] - The company relies on a limited number of suppliers, which could adversely affect its ability to meet customer demand if supplier issues arise[51] - The company relies on third-party information systems for critical operations, and any failure could disrupt business and compromise data integrity[111] Strategic Initiatives and Investments - The company has received over $220 million in funding to date to support its operations and expansion efforts[71] - The company announced a US$80 million investment in Insighta to develop and commercialize a multi-cancer early detection technology called "FRAGMA" in July 2023[122] - In May 2024, the company acquired 100% of the membership interests in Europa Group, a leading distributor of sports nutrition and health products in the U.S.[122] - The company completed the acquisition of Europa Sports Partners in August 2024, enhancing its distribution capabilities[200] - IM8 Health, a premium supplements brand, was launched in November 2024, targeting the global wellness market[212] Shareholder and Governance Issues - The company has authorized a share repurchase program of up to $20 million for Class A Ordinary Shares over 24 months, with $2.45 million spent to repurchase 251,390 shares as of November 29, 2024[171] - Mr. Yeung owns approximately 10.8% of total shares but controls 70.8% of voting power due to the dual-class share structure, limiting influence of Class A shareholders[160] - The company has a dual-class voting structure, with Class A shares having one vote and Class B shares having twenty votes, potentially discouraging change of control transactions[159] - The company may issue additional securities without shareholder approval, potentially diluting existing ownership interests[181] - Future resales of shares by significant shareholders may lead to increased volatility and downward pressure on the share price[158] Future Outlook and Growth Potential - The company anticipates continued significant losses as it invests in expanding into consumer health and developing international markets[72] - The company plans to pursue additional acquisitions or strategic partnerships to expand offerings and market reach, but suitable opportunities may not be available or completed on favorable terms[124] - The company may not fully realize anticipated synergies from recent acquisitions, including a multi-cancer early detection test with Insighta[123] - The company is classified as an "emerging growth company," allowing it to take advantage of reduced SEC reporting requirements, which may affect investor attractiveness[163] Legal and Data Privacy Concerns - The company faces substantial legal exposure relating to data privacy and protection, with potential fines up to €20 million or 4% of global revenue for non-compliance with GDPR[133] - The company may face increased scrutiny and potential litigation as a public entity, impacting its financial condition and operations[162]

Core Insights - IM8 hosted an event called IM8 Vibrante to promote its vision of making elite wellness accessible to all, featuring nearly 150 attendees including wellness influencers and medical advisors [1][2] - The event highlighted IM8's commitment to blending science and holistic health, showcasing its flagship product, Daily Ultimate Essentials, which is designed to replace 16 different supplements [7] Company Overview - IM8 is co-founded by David Beckham and focuses on premium core nutrition, combining advanced science with natural ingredients to promote health [7] - The flagship product, Daily Ultimate Essentials, is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, and sweeteners [7] Event Highlights - David Beckham shared his personal wellness journey and the positive impact of IM8 on his energy and focus [3] - A panel discussion featured experts discussing longevity and healthspan, emphasizing the importance of quality of life alongside lifespan [3] - Dr. Jim Green presented ongoing research on advanced aging in space, in collaboration with Oxford University and SpaceX [3] Community Engagement - The event underscored the strength of the IM8 ambassador and creator community, which plays a vital role in promoting wellness and engaging audiences [5] - Influencers from platforms like TikTok and Meta showcased their commitment to wellness, aligning with IM8's mission [5] Leadership Perspective - Danny Yeung, CEO of IM8, expressed pride in the progress made and the inspiring energy of the community at the event [6]

Core Insights - IM8 has expanded its Scientific Advisory Board (SAB) by adding Dr. Jeremy London and Dr. Amy Shah, enhancing its commitment to innovation in science, longevity, and human performance [1][4] Company Overview - IM8 is a premium supplements brand co-founded by David Beckham, focusing on delivering science-backed health solutions [14] - The company’s flagship product, Daily Ultimate Essentials, is designed to replace up to 16 supplements, promoting energy, immunity, digestion, and longevity [12] New Advisory Board Members - Dr. Amy Shah is an integrative medicine physician specializing in gut health, hormonal balance, and nutrition, bringing evidence-based wellness solutions to IM8 [2] - Dr. Jeremy London is a cardiothoracic surgeon with over 25 years of experience, recognized for his work in preventive cardiovascular health and minimally invasive treatments [3] Existing Advisory Board Members - Dr. Dawn Mussallem, an integrative oncologist at Mayo Clinic, has over 20 years of clinical experience and focuses on lifestyle medicine [5] - Dr. Jim Green, former Chief Scientist of NASA, contributes expertise in space science and biomedical innovations [6] - Dr. James DiNicolantonio, a cardiovascular research scientist, has authored over 250 academic publications, enhancing IM8's nutritional offerings [7] - Dr. Suzanne Devkota, a microbiome research expert, emphasizes the connection between microbiome health and overall wellness [8] - Dr. David Katz, a preventive medicine expert, has around 250 peer-reviewed publications and has significantly influenced IM8's nutrition solutions [9][10] - Dr. Stephen Anton, a professor specializing in aging and metabolic health, focuses on lifestyle factors and their impact on aging [11] Market Context - The global supplements market is valued at $152 billion and is projected to reach $300 billion by 2028, driven by increasing consumer demand for scientifically-backed products [13]

Core Insights - IM8 has expanded its Scientific Advisory Board (SAB) by adding Dr. Jeremy London and Dr. Amy Shah, enhancing its commitment to innovation in science, longevity, and human performance [1][4] Company Overview - IM8 is a premium supplements brand co-founded by David Beckham, focusing on delivering science-backed health solutions [14] - The company’s flagship product, Daily Ultimate Essentials, is designed to replace up to 16 supplements, promoting energy, immunity, digestion, and longevity [12] New Advisory Board Members - Dr. Amy Shah is an integrative medicine physician specializing in gut health, hormonal balance, and nutrition, bringing evidence-based wellness solutions to IM8 [2] - Dr. Jeremy London is a cardiothoracic surgeon with over 25 years of experience, recognized for his work in preventive cardiovascular health and minimally invasive treatments [3] Existing Advisory Board Members - Dr. Dawn Mussallem, an integrative oncologist at Mayo Clinic, has over 20 years of clinical experience and focuses on lifestyle medicine [5] - Dr. Jim Green, former Chief Scientist of NASA, contributes expertise in space science and biomedical innovations [6] - Dr. James DiNicolantonio, a cardiovascular research scientist, has authored over 250 academic publications, enhancing IM8's nutritional offerings [7] - Dr. Suzanne Devkota, a microbiome research expert, emphasizes the connection between microbiome health and overall wellness [8] - Dr. David Katz, a preventive medicine expert, has significantly influenced IM8's nutrition and healthcare strategies with around 250 peer-reviewed publications [9][10] - Dr. Stephen Anton, a professor specializing in aging and metabolic health, focuses on lifestyle factors and their impact on aging [11] Market Context - The global supplements market is currently valued at $152 billion and is projected to reach $300 billion by 2028, driven by increasing consumer demand for scientifically-backed products [13]

Core Insights - Prenetics Global Limited will participate in the 37th Annual ROTH Conference from March 16 to March 18, 2025 [1] - The CEO Danny Yeung and President of Americas David Vanderveen will host one-on-one meetings with investors and participate in a panel discussion on Longevity and Supplementation [2] Company Overview - Prenetics is a leading health sciences company focused on advancing consumer and clinical health, with initiatives including the IM8 health and wellness brand and Insighta, a $200 million venture for multi-cancer early detection technologies [4] - The company's commitment is to enhance life through science, leveraging its various units to create a global impact on health [4]